Analyst Price Targets — ONC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 14, 2026 9:39 am | — | Barclays | $403.00 | $303.96 | TheFly | BeOne Medicines price target lowered to $403 from $409 at Barclays |
| July 13, 2026 1:01 am | — | Jefferies | $380.00 | $298.70 | TheFly | BeOne Medicines upgraded to Buy from Hold at Jefferies |
| July 7, 2026 1:13 pm | — | Truist Financial | $416.00 | $308.46 | TheFly | BeOne Medicines price target raised to $416 from $413 at Truist |
| July 7, 2026 11:29 am | — | RBC Capital | $451.00 | $309.46 | TheFly | BeOne Medicines price target raised to $451 from $436 at RBC Capital |
| June 2, 2026 11:16 am | Leonid Timashev | RBC Capital | $436.00 | $276.47 | StreetInsider | BeOne Medicines (ONC) PT Raised to $436 at RBC Capital |
| May 15, 2026 2:56 pm | — | Leerink Partners | $367.00 | $293.76 | TheFly | BeOne Medicines price target raised to $367 from $364 at Leerink |
| May 7, 2026 1:15 pm | — | Morgan Stanley | $395.00 | $312.05 | TheFly | BeOne Medicines price target raised to $395 from $389 at Morgan Stanley |
| May 7, 2026 10:41 am | Michael Schmidt | Guggenheim | $420.00 | $313.32 | TheFly | BeOne Medicines price target raised to $420 from $410 at Guggenheim |
| May 7, 2026 9:26 am | — | Barclays | $409.00 | $313.32 | TheFly | BeOne Medicines price target raised to $409 from $405 at Barclays |
| May 4, 2026 9:08 am | Yanan Zhu | Wells Fargo | $400.00 | $293.86 | TheFly | BeOne Medicines initiated with an Overweight at Wells Fargo |
Latest News for ONC
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed…
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell…
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton's tyrosine kinase (BTK) degrader, demonstrated durable…
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the…
BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ONC.
U.S. House Trading
No House trades found for ONC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.